Shanghai Fosun Pharmaceutical (02196): Ketoprofen patches approved for clinical trials.
Fosun Pharma (02196) announced that its holding subsidiary Shanghai Chaohui Pharmaceutical Co., Ltd. (referred to as "Chaohui Pharmaceutical") recently received approval from the National Medical Products Administration to conduct clinical trials of ketoprofen patch. Chaohui Pharmaceutical plans to conduct Phase III clinical trials of this drug in China when the conditions are met. This drug is a chemical drug primarily used for (1) analgesia and anti-inflammatory effects on the following diseases and symptoms: lumbago (myofascial pain syndrome, degenerative changes of the spine, intervertebral disc disease, and lumbar sprain), osteoarthritis, adhesive capsulitis, tendinitis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), muscle pain, swelling and pain due to trauma, (2) local pain relief for rheumatoid arthritis.
Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd. ("Chaohui Pharmaceutical"), recently received approval from the National Medical Products Administration to conduct clinical trials of Ketoprofen patches. Chaohui Pharmaceutical plans to conduct Phase III clinical trials of this drug in China once the conditions are met. This drug is a chemical substance mainly used for pain relief and inflammation in the following conditions: low back pain (muscle fascia pain syndrome, degenerative changes of the spine, intervertebral disc diseases and lumbar sprains), osteoarthritis, shoulder periarthritis, tendon and tendon sheath inflammation, peritendinitis, lateral epicondylitis (tennis elbow), muscle pain, swelling and pain caused by trauma, and local pain relief in rheumatoid arthritis.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
